Reddy’s Reveals Strategy For Denosumab To ‘Facilitate’ Abatacept Opportunity
Indian Firm ‘Comfortable’ With 25% EBITDA, gRevlimid Cash Bolsters R&D
In a thorough financial Q3 earnings call, generics and biosimilars giant Dr Reddy’s revealed several key details about its plans to “be in the neighborhood for some time” with a 25%+ EBITDA margin, including through the planned near- and medium-term launches of denosumab, abatacept and semaglutide.
